Cantor Fitzgerald Reiterates Overweight on AVITA Medical, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on AVITA Medical (NASDAQ:RCEL) and maintained a $20 price target on the company's stock.
November 21, 2023 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn reaffirmed an Overweight rating on AVITA Medical with a $20 price target, indicating a positive outlook for the stock.
The reiteration of an Overweight rating and the maintenance of a $20 price target by a reputable analyst like Ross Osborn can instill confidence in investors and potentially lead to a positive short term impact on RCEL's stock price. The analyst's endorsement serves as a bullish signal to the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100